Johnson & Johnson's SGLT2 inhibitor Invokana (canagliflozin)--among a handful of drugs in the new category of DPP-4 drugs for diabetes--not only took a big jump in sales for the first quarter but also made some significant market-share gains.
San Diego biotech Ichor Medical Systems stands to earn up to $85 million, plus royalties, if its new partnership with Johnson & Johnson's Janssen hits the right notes. The companies announced plans this week to develop DNA vaccines for hepatitis B using Ichor's TriGrid electroporation technology for clinical administration.
IBM increased its presence in the device world in a major way, announcing a collaboration around famous supercomputer Watson with Medtronic, Johnson & Johnson and Apple.
Johnson & Johnson's device strategy of divesting its worst performing businesses--while pushing forward with the rollout of innovative products--has yet to pay off. But the company is hopeful that it can return the business to sales growth over the next year.
J&J's Janssen Pharmaceuticals just announced a partnership involving the use of Ichor Medical Systems' TriGrid electroporation technology to deliver a DNA vaccine for hepatitis B.
Johnson & Johnson revealed that its hepatitis C drug Olysio succumbed to U.S. competition. With Gilead Sciences' two-in-one pill Harvoni and AbbVie's Viekira Pak now on the scene, the J&J drug saw sales drop by two-thirds--and it was one of J&J's biggest pharma-growth drivers last year.
Janssen Pharmaceuticals has paired up with Ichor Medical Systems to develop and market DNA-based vaccine products to treat chronic hepatitis B. The partners will use the startup's TriGrid electroporation technology for clinical administration of a DNA vaccine.
A Dutch immuno-oncology player that has received venture funding from Johnson & Johnson, Novartis and Pfizer is preparing to list on Nasdaq. The company--Merus--hopes to raise upward of €100 million ($107 million) to advance its pipeline of bispecific IgG antibodies into the clinic and through early-phase trials.
Johnson & Johnson's Ethicon division received clearance from the FDA for an expanded indication of its Evarrest patch, which can now be used to help control bleeding during adult liver surgery.
Why didn't Johnson & Johnson buy Pharmacyclics? Good question--and one The Wall Street Journal posed to CEO Alex Gorsky in a recent interview in Tokyo.